Funding for this research was provided by:
American Society of Clinical Oncology Career Development Award (n/a)
Breast Cancer Research Foundation (n/a)
Dana-Farber Cancer Institute Women’s Cancers Program Executive Council Personalized Medicine Award (n/a)
South-Eastern Norway Regional Health Authority (2016102 and 2013069)
Norwegian Cancer Society (6817564)
Received: 29 July 2020
Accepted: 15 November 2020
First Online: 30 November 2020
Ethics approval and consent to participate
: The protocol was approved by the Dana-Farber/Harvard Cancer Center (DF/HCC) Scientific Review Committee and Institutional Review Board. All study participants provided written informed consent prior to any study-related procedures.
: Not applicable.
: Harris: Member, Novometrics LLC, IQ Medical Imaging LLC; Scientific Advisory Board, Fovia Inc.Krop: Institutional research funding from Genentech/Roche, Pfizer, and Daiichi-Sankyo; advisory board participant/consultant for Genentech/Roche, Daiichi-Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Bristol-Myers Squibb, Celltrion Pharma, Merck (DSMC), Novartis (DSMB); honoraria from Genentech/Roche, Daiichi-Sankyo, Macrogenics, Context Therapeutics, Taiho.Morganstern: advisory role and honoraria for PUMA pharmaceuticals.Winer: Institutional research funding from Genentech/Roche; consultant/honoraria from Genentech/Roche, GSK and Seattle Genetics (each < $5000).Lin: Consulting for Puma, Seattle Genetics, Daichii Sankyo though none would have a financial interest in the results or materials of this study.